Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Radical cystectomy

7 evidence topics · 9 sources

Guideline recommendation: radical cystectomy as the standard option for BCG-unresponsive disease

“Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.” (opens the source at this quote in a new tab)

“Offer an RC to patients with BCG-unresponsive tumours.” (opens the source at this quote in a new tab)

“Early RC is recommended in patients with BCG-unresponsive tumours and should be considered in BCG-relapsing HG tumours, as discussed in Section 7.8 and Table 7.5.” (opens the source at this quote in a new tab)

“A delay in RC may lead to decreased disease-specific survival” (opens the source at this quote in a new tab)

“Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.” (opens the source at this quote in a new tab)

“However, the potential benefit of RC must be weighed against its risks, morbidity, and impact on quality of life (QoL) and discussed with patients in a shared decision-making process.” (opens the source at this quote in a new tab)

“Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).” (opens the source at this quote in a new tab)

Standard of care, morbidity, and deferral of surgery
Upfront radical cystectomy compared with bladder-sparing therapy: multicenter retrospective cohort

“Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were no significant differences in MFS (HR 0.88, 95% CI 0.53–1.46; P = 0.62), CSS (HR 0.91, 95% CI 0.54–1.53; P = 0.73), or OS (HR 1.31, 95% CI 0.91–1.90; P = 0.15) between patients who received upfront RC compared to those receiving BST at time of diagnosis of BCG‐unresponsive NMIBC (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Although adverse oncological outcomes began to rise 12 months after diagnosis, the rate of dying from bladder cancer were similar at 14% in both the upfront RC and BST groups at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The low rates of metastasis and death for patients who underwent BST are reassuring, but comparison with RC is impacted by selection bias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Timing of radical cystectomy after BCG failure